The following is a complete listing of all claims in the application, with an indication of the status of each:

Listing of claims:

1-20. (Cancelled)

21. (Previously presented) A compound of the general formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C_1 to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1, where X^1 = H, Cl, Br, I or F;

R_1 is H, or C_1 to C_7 alkyl, phenyl, or substituted phenyl;

R_2, R_3, R_4 and R_5 are H or C_1 to C_7 alkyl, and R_1, R_2, R_3, R_4 and R_5 may be the same or different; and

X is CH_2 or a saturated or unsaturated C_2 carbon chain.

22. (Previously presented) A compound of formula



23. (Previously presented) A compound of formula



24. (Previously presented) A compound of formula



25. (Previously presented) A compound of formula



26. (Previously presented) A compound of formula



27. (Currently amended) A method of treatment of a condition or disorders related to cannabinoid-regulated systems in a patient in need thereof, wherein if said compound is an agonist of a CB1 receptor then said condition is selected from the group consisting of acute pain; chronic pain; loss of appetite, and nausea and vomiting; and wherein if said compound is a silent antagonist of a CB1 receptor then said condition is obesity;

comprising the step of

administering to said patient ~~a quantity of~~ a compound of formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C_1 to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1, where X^1 = H, Cl, Br, I or F;

R_1 is H, C_1 to C_7 alkyl, phenyl, or substituted phenyl;

R_2, R_3, R_4 and R_5 are H or C_1 to C_7 alkyl, and R_1, R_2, R_3, R_4 and R_5 may be the same or different; and

X is CH_2 or a saturated or unsaturated C_2 carbon chain,

wherein said compound is administered in a quantity sufficient to ameliorate symptoms of said condition or disorder.

28. (Currently amended) A method for treating pain in a patient comprising administering to said patient an effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulfonamide moiety, and said agonist has the chemical formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C_1 to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1, where X^1 = H, Cl, Br, I or F;

R_1 is H, C_1 to C_7 alkyl, phenyl, or substituted phenyl;

R_2, R_3, R_4 and R_5 are H or C_1 to C_7 alkyl, and R_1, R_2, R_3, R_4 and R_5 may be the same or different; and

X is CH_2 or a saturated or unsaturated C_2 carbon chain, with the proviso that if R is CH_3 then X must be CH_2 or a saturated C_2 carbon chain.

29. (Previously presented) The method of claim 28 wherein said agonist is selected from the group consisting of



and



30. (Currently amended) A method for treating nausea in a patient comprising administering to said patient an effective dose of an agonist of a CB1 cannabinoid receptor wherein said agonist includes a sulfonamide moiety, and wherein said agonist has the chemical formula



where

m is an integer from 0 to 5;

n is an integer from 0 to 5;

R is C_1 to C_7 alkyl, cycloalkyl, phenyl, hydroxy, alkyl hydroxy, substituted phenyl, or CH_2X^1, where X^1 = H, Cl, Br, I or F;

R_1 is H, C_1 to C_7 alkyl, phenyl, or substituted phenyl;

R_2, R_3, R_4 and R_5 are H or C_1 to C_7 alkyl, and R_1, R_2, R_3, R_4 and R_5 may be the same or different; and

X is CH_2 or a saturated or unsaturated C_2 carbon chain, with the proviso that if R is CH_3 then X must be CH_2 or a saturated C_2 carbon chain.

31. (Previously presented) The method of claim 13, wherein said agonist is selected from the group consisting of



and



32. (Currently amended) A method for treating obesity in a patient comprising administering to said patient an effective dose of a silent antagonist of a CB1 cannabinoid receptor wherein said ~~agonist~~ silent antagonist includes a sulfonamide moiety, and wherein said ~~agonist~~ silent antagonist has the chemical formula